---
schema_version: "secwatch.filing_event.v1"
accession: "0001829126-25-009221"
form_type: "8-K"
ticker: "NTHI"
cik: "0001979414"
company_name: "NEONC TECHNOLOGIES HOLDINGS, INC."
filed_at: "2025-11-14T23:59:59+00:00"
generated_at: "2026-05-16T19:57:05.651307+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# NeOnc Q3 net loss $8.6M ($0.45/diluted); NEO100 Phase 2a shows 21% response rate; board changes

## Summary
- Net loss of $8.6M ($0.45 diluted EPS) vs $2.2M ($0.12) in Q3 2024; G&A up $903k vs $244k YoY.
- NEO100 Phase 2a in recurrent brain cancer: 21% response rate vs <8% historical; 44% six-month PFS; 33% alive >=18 months.
- NEO212 received FDA authorization to proceed to Phase II; Phase I final cohort dosing on track for Q4 2025.
- NuroMENA subsidiary signed $50M strategic partnership with Quazar Investment, appointed H.H. Sheikh Nahyan as Exec Chairman.
- Dr. Ming-Fu Chiang re-elected to Board after Ishwar K. Puri resigned due to USC objection.

## SEC filing metadata
- accession: 0001829126-25-009221
- form_type: 8-K
- ticker: NTHI
- cik: 0001979414
- company_name: NEONC TECHNOLOGIES HOLDINGS, INC.
- filed_at: 2025-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1979414/000182912625009221/0001829126-25-009221-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1979414/000182912625009221/neonctechnologies_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001829126-25-009221
- JSON: https://secwatch.observer/filing/0001829126-25-009221.json
- Plain text: https://secwatch.observer/filing/0001829126-25-009221.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.